MA56047A - Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting - Google Patents

Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting

Info

Publication number
MA56047A
MA56047A MA056047A MA56047A MA56047A MA 56047 A MA56047 A MA 56047A MA 056047 A MA056047 A MA 056047A MA 56047 A MA56047 A MA 56047A MA 56047 A MA56047 A MA 56047A
Authority
MA
Morocco
Prior art keywords
compositions
compounds
treatment
diseases associated
sting activity
Prior art date
Application number
MA056047A
Other languages
English (en)
Inventor
Jason Katz
William R Roush
Shankar Venkatraman
Original Assignee
Ifm Due Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifm Due Inc filed Critical Ifm Due Inc
Publication of MA56047A publication Critical patent/MA56047A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056047A 2019-05-29 2020-05-29 Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting MA56047A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962854288P 2019-05-29 2019-05-29

Publications (1)

Publication Number Publication Date
MA56047A true MA56047A (fr) 2022-04-06

Family

ID=71787083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056047A MA56047A (fr) 2019-05-29 2020-05-29 Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting

Country Status (5)

Country Link
US (1) US20220227760A1 (fr)
EP (1) EP3976584A1 (fr)
JP (1) JP2022535743A (fr)
MA (1) MA56047A (fr)
WO (1) WO2020243519A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120004785A (zh) 2018-07-03 2025-05-16 诺华制药股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
JP2023554393A (ja) * 2020-12-16 2023-12-27 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
US20240051970A1 (en) * 2020-12-16 2024-02-15 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP4267129A1 (fr) 2020-12-22 2023-11-01 IFM Due, Inc. Méthodes de traitement du cancer
EP4267128A1 (fr) 2020-12-22 2023-11-01 IFM Due, Inc. Méthodes de traitement du cancer
JP2024500874A (ja) 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
US20240060982A1 (en) * 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer
EP4274824A1 (fr) 2021-01-08 2023-11-15 IFM Due, Inc. Composés hétérobicycliques ayant une urée ou un analogue et leurs compositions pour le traitement d'états associés à une activité de sting
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
WO2024064358A1 (fr) 2022-09-23 2024-03-28 Ifm Due, Inc. Composés et compositions pour le traitement d'affections associées à une activité de sting

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022605A1 (fr) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
CN102812023A (zh) * 2010-01-13 2012-12-05 韩国巴斯德研究所 抗感染吡啶并(1,2-a)嘧啶类
US8497285B2 (en) 2010-12-03 2013-07-30 The Trustees Of The University Of Pennsylvania Therapy of autoimmune colitis using a TIP60 inhibitor
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
CA2927009C (fr) 2013-10-21 2019-04-23 Drexel University Utilisation d'agonistes de sting pour traiter une infection chronique par le virus de l'hepatite b
WO2015131005A1 (fr) * 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles et leurs analogues associés comme inhibiteurs de bromodomaine bet
EP3632915A1 (fr) * 2014-11-27 2020-04-08 Genentech, Inc. Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300
JP7636322B2 (ja) * 2018-11-15 2025-02-26 アンスティテュ・ギュスターヴ・ルシー 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用
JP2022507697A (ja) * 2018-11-19 2022-01-18 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Also Published As

Publication number Publication date
WO2020243519A1 (fr) 2020-12-03
EP3976584A1 (fr) 2022-04-06
US20220227760A1 (en) 2022-07-21
JP2022535743A (ja) 2022-08-10

Similar Documents

Publication Publication Date Title
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA56047A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
MA53096A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
MA44734A (fr) Composés et compositions destinés au traitement d'états associés à une activité de nlrp
MA53095A (fr) Composés et compositions pour traiter des états pathologiques associés à une activité de sting
MA56193A (fr) Composés et compositions pour traiter des états associés à une activité de sting
DK3906066T5 (da) Geneterapikonstruktioner til behandling af wilsons sygdom
MA55138A (fr) Composés et compositions pour traiter des états pathologiques associés à une activité de sting
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
EP3873335A4 (fr) Caractérisation de l'efficacité thérapeutique d'une neurostimulation
EP3755805A4 (fr) Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
MA54753A (fr) Composés et compositions pour traiter des états pathologiques associés à une activité de sting
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3963063A4 (fr) Compositions pour le traitement de la maladie de pompe
EP3906241A4 (fr) Inhibiteurs de l'activité cgas utilisés à titre d'agents thérapeutiques
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
EP3846821A4 (fr) Polythérapie destinée au traitement d'une maladie hépatique
EP3606520A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA54741A (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
EP3749322A4 (fr) Composés et méthodes de traitement d'une dépendance et de troubles associés
EP3906229A4 (fr) Inhibiteurs de l'activité cgas à titre d'agents thérapeutiques
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire